Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxim Norkin

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Hematology/Oncology and Stem Cell Therapy|October 21, 2019
Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipientsForat Lutfi, William Paul Skelton Iv, Yu Wang, et al.
Journal of Clinical Apheresis|May 31, 2017
Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantationJan S Moreb, Michael Byrne, Ilicia Shugarman, et al.
Clinical Transplantation|May 25, 2016
Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experienceLakshmikanth Katragadda, Lindsay M McCullough, Yunfeng Dai, et al.
Expert Opinion on Biological Therapy|December 25, 2025
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S Azevedo, Zohra Nooruddin, Sumeet Bhatia, et al.
Leukemia Research|May 2, 2016
A new model to predict remission status in AML patients based on day 14 bone marrow biopsyMaxim Norkin, Myron Chang, Qi An, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 4, 2023
Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinomaGeorge M Ramzy, Maxim Norkin, Thibaud Koessler, et al.
Leukemia & Lymphoma|November 1, 2018
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scalesJason Tay, Ravi Vij, Maxim Norkin, et al.
Blood Cancer Journal|November 28, 2017
Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemiaMaxim Norkin, Lakshmikanth Katragadda, Fei Zou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 25, 2015
European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care StandardsChloe Anthias, Paul V O'Donnell, Deidre M Kiefer, et al.
British Journal of Haematology|April 3, 2020
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromesChristopher R Cogle, Bradley Collins, Daniel Turner, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Hematology/Oncology and Stem Cell Therapy|October 21, 2019
Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipientsForat Lutfi, William Paul Skelton Iv, Yu Wang, et al.
Journal of Clinical Apheresis|May 31, 2017
Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantationJan S Moreb, Michael Byrne, Ilicia Shugarman, et al.
Clinical Transplantation|May 25, 2016
Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experienceLakshmikanth Katragadda, Lindsay M McCullough, Yunfeng Dai, et al.
Expert Opinion on Biological Therapy|December 25, 2025
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S Azevedo, Zohra Nooruddin, Sumeet Bhatia, et al.
Leukemia Research|May 2, 2016
A new model to predict remission status in AML patients based on day 14 bone marrow biopsyMaxim Norkin, Myron Chang, Qi An, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 4, 2023
Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinomaGeorge M Ramzy, Maxim Norkin, Thibaud Koessler, et al.
Leukemia & Lymphoma|November 1, 2018
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scalesJason Tay, Ravi Vij, Maxim Norkin, et al.
Blood Cancer Journal|November 28, 2017
Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemiaMaxim Norkin, Lakshmikanth Katragadda, Fei Zou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 25, 2015
European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care StandardsChloe Anthias, Paul V O'Donnell, Deidre M Kiefer, et al.
British Journal of Haematology|April 3, 2020
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromesChristopher R Cogle, Bradley Collins, Daniel Turner, et al.
Pageof 6